PMID- 27742581
OWN - NLM
STAT- MEDLINE
DCOM- 20180816
LR  - 20220316
IS  - 1090-2139 (Electronic)
IS  - 0889-1591 (Linking)
VI  - 60
DP  - 2017 Feb
TI  - Oxidative stress predicts depressive symptom changes with omega-3 fatty acid 
      treatment in coronary artery disease patients.
PG  - 136-141
LID - S0889-1591(16)30467-6 [pii]
LID - 10.1016/j.bbi.2016.10.005 [doi]
AB  - BACKGROUND: Antidepressant efficacy of omega-3 polyunsaturated fatty acid (n-3 
      PUFA) treatment in coronary artery disease (CAD) patients remains unpredictable. 
      N-3 PUFA can mitigate oxidative stress, which is common in CAD and may contribute 
      to depressive symptoms. This study investigated whether greater pre-treatment 
      oxidative stress, measured by the ratios of late-stage lipid peroxidation markers 
      (malondialdehyde [MDA], 4-hydroxy-2-nonenal [4-HNE], and 8-isoprostane [8-ISO]) 
      to an early-stage marker (lipid hydroperoxides [LPH]), predicted n-3 PUFA 
      antidepressant benefits in CAD. METHODS: This was a secondary analysis of CAROTID 
      (CAD Randomized Omega-3 Trial in Depression, NCT00981383). Patient demographics 
      and medical characteristics were collected. Depressive symptoms were measured 
      using the 17-item Hamilton Depression Rating Scale (HAM-D). Patients were then 
      randomized to receive either 1.9g/day n-3 PUFA or placebo for 12weeks, after 
      which HAM-D scores were reassessed. Baseline LPH, 4-HNE, 8-ISO, MDA and n-3 PUFA 
      concentrations were analysed from fasting blood. RESULTS: Seventy-nine patients 
      (age=61.1+/-8.5, 76% male, HAM-D=7.5+/-6.1) were included (n=45 placebo, n=34 n-3 
      PUFA). In the n-3 PUFA group, higher baseline ratios of MDA/LPH (primary 
      analysis: F(1,33)=6.20, beta=-0.35, p=0.018), 4-HNE/LPH (exploratory analysis: 
      F(1,33)=5.35, beta=-0.32, p=0.027), and 8-ISO/LPH (exploratory analysis: 
      F(1,33)=6.10, beta=-0.33, p=0.019), indicating higher oxidative stress, were 
      associated with greater depressive symptom improvement. In each model, higher 
      baseline EPA+DHA concentrations independently predicted depressive symptom 
      improvement with n-3 PUFA (MDA/LPH: F(1,33)=11.05, p=0.002; 4-HNE/LPH: 
      F(1,33)=11.36, p=0.002; 8-ISO/LPH: F(1,33)=13.15, p=0.001). No associations were 
      observed in the placebo group. CONCLUSIONS: n-3 PUFA may be more likely to 
      improve depressive symptoms in CAD patients with pre-treatment evidence of 
      oxidative stress.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Mazereeuw, Graham
AU  - Mazereeuw G
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Herrmann, Nathan
AU  - Herrmann N
AD  - Hurvitz Brain Sciences Program, Sunnybrook Research Institute and Department of 
      Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Andreazza, Ana C
AU  - Andreazza AC
AD  - Centre for Addiction and Mental Health, and Departments of 
      Pharmacology/Toxicology and Psychiatry, University of Toronto, Toronto, Ontario, 
      Canada.
FAU - Scola, Gustavo
AU  - Scola G
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Ma, David W L
AU  - Ma DWL
AD  - Department of Human Health and Nutritional Sciences, University of Guelph, 
      Guelph, Ontario, Canada.
FAU - Oh, Paul I
AU  - Oh PI
AD  - University Health Network at Toronto Rehabilitation Institute, Toronto, Ontario, 
      Canada.
FAU - Lanctot, Krista L
AU  - Lanctot KL
AD  - Hurvitz Brain Sciences Program, Sunnybrook Research Institute and Departments of 
      Psychiatry and Pharmacology/Toxicology, University of Toronto, Toronto, Ontario, 
      Canada. Electronic address: Krista.Lanctot@sunnybrook.ca.
LA  - eng
PT  - Journal Article
DEP - 20161011
PL  - Netherlands
TA  - Brain Behav Immun
JT  - Brain, behavior, and immunity
JID - 8800478
RN  - 0 (Antidepressive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Fatty Acids, Omega-3)
SB  - IM
MH  - Antidepressive Agents/therapeutic use
MH  - Biomarkers/blood
MH  - Coronary Artery Disease/*blood/drug therapy
MH  - Depression/*blood
MH  - Fatty Acids, Omega-3/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Oxidative Stress/*physiology
OTO - NOTNLM
OT  - Cardiovascular
OT  - Coronary artery disease
OT  - DHA
OT  - Depression
OT  - Docosahexaenoic acid
OT  - EPA
OT  - Eicosapentaenoic acid
OT  - Fish oil
OT  - Heart disease
OT  - Hydroperoxide
OT  - Hydroxynonenal
OT  - Isoprostane
OT  - Lipid peroxidation
OT  - Malondialdehyde
OT  - Mood
OT  - Omega-3 fatty acid
OT  - Oxidative stress
EDAT- 2016/10/19 06:00
MHDA- 2018/08/17 06:00
CRDT- 2016/10/16 06:00
PHST- 2016/08/18 00:00 [received]
PHST- 2016/09/23 00:00 [revised]
PHST- 2016/10/08 00:00 [accepted]
PHST- 2016/10/19 06:00 [pubmed]
PHST- 2018/08/17 06:00 [medline]
PHST- 2016/10/16 06:00 [entrez]
AID - S0889-1591(16)30467-6 [pii]
AID - 10.1016/j.bbi.2016.10.005 [doi]
PST - ppublish
SO  - Brain Behav Immun. 2017 Feb;60:136-141. doi: 10.1016/j.bbi.2016.10.005. Epub 2016 
      Oct 11.